title: Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.
abstract: We compare the design, mechanism of action, and clinical efficacy of two recently licensed paradigm shifting vaccines. Zostavax is the first vaccine licensed to prevent disease in patients already infected with a pathogen, and is contrasted with Gardasil and Cervarix, the first vaccines designed and licensed specifically to prevent cancers.
authors: Translational Research Institute, The University of Queensland Diamantina Institute, PO Box 6116, Buranda Queensland 4102, Australia. i.frazer@uq.edu.au
authors: Ian H
authors: IH
authors: Frazer
authors: Myron J
authors: MJ
authors: Levin
mesh_terms: D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology*; D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D006562:Herpes Zoster / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D053918:Papillomavirus Vaccines / Q000235:genetics / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines